Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Elizabeth Garrett-Mayer and David Marshall.
Connection Strength

0.448
  1. Opfermann KJ, Wahlquist AE, Garrett-Mayer E, Shridhar R, Cannick L, Marshall DT. Adjuvant radiotherapy and lymph node status for pancreatic cancer: results of a study from the Surveillance, Epidemiology, and End Results (SEER) Registry Data. Am J Clin Oncol. 2014 Apr; 37(2):112-6.
    View in: PubMed
    Score: 0.137
  2. Esnaola NF, Chaudhary UB, O'Brien P, Garrett-Mayer E, Camp ER, Thomas MB, Cole DJ, Montero AJ, Hoffman BJ, Romagnuolo J, Orwat KP, Marshall DT. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014 Mar 15; 88(4):837-44.
    View in: PubMed
    Score: 0.137
  3. Marshall DT, Savage SJ, Garrett-Mayer E, Keane TE, Hollis BW, Horst RL, Ambrose LH, Kindy MS, Gattoni-Celli S. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab. 2012 Jul; 97(7):2315-24.
    View in: PubMed
    Score: 0.120
  4. Hollis BW, Marshall DT, Savage SJ, Garrett-Mayer E, Kindy MS, Gattoni-Celli S. Vitamin D3 supplementation, low-risk prostate cancer, and health disparities. J Steroid Biochem Mol Biol. 2013 Jul; 136:233-7.
    View in: PubMed
    Score: 0.031
  5. Watkins JM, Marshall DT, Patel S, Giglio P, Herrin AE, Garrett-Mayer E, Jenrette JM. High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas. J Neurooncol. 2009 Jul; 93(3):343-8.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.